万泰生物
(603392)
| 流通市值：876.73亿 | | | 总市值：876.73亿 |
| 流通股本：12.65亿 | | | 总股本：12.65亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 400,625,153.87 | 2,245,403,245.65 | 1,948,111,396.63 | 1,366,045,101.74 |
| 营业收入 | 400,625,153.87 | 2,245,403,245.65 | 1,948,111,396.63 | 1,366,045,101.74 |
| 二、营业总成本 | 464,970,086.22 | 2,395,621,317.62 | 1,928,979,981.89 | 1,289,398,978.35 |
| 营业成本 | 134,003,165.48 | 759,044,722.33 | 548,825,057.73 | 366,518,953.28 |
| 税金及附加 | 2,204,754.82 | 23,100,236.89 | 14,267,199.93 | 11,518,532.49 |
| 销售费用 | 103,473,018.76 | 438,392,131.59 | 443,746,679.62 | 314,996,757.34 |
| 管理费用 | 92,912,751.33 | 347,100,195.32 | 237,739,182.71 | 153,840,741.76 |
| 研发费用 | 138,625,170.95 | 886,051,943.23 | 726,214,438.31 | 479,931,276.6 |
| 财务费用 | -6,248,775.12 | -58,067,911.74 | -41,812,576.41 | -37,407,283.12 |
| 其中:利息费用 | 2,026,170.05 | 8,324,928.73 | 4,368,762.54 | 3,209,150.09 |
| 其中:利息收入 | 6,681,311.33 | 59,455,687.13 | 50,024,611.21 | 39,797,638.07 |
| 加:公允价值变动收益 | 8,817,746.15 | 36,707,335.76 | 13,336,212.46 | 8,554,260.2 |
| 加:投资收益 | 22,017,103.25 | 109,636,079.11 | 93,453,414.67 | 65,965,630.78 |
| 资产处置收益 | -15,909.99 | 7,923,472.52 | 1,183,739.81 | 102,259.03 |
| 资产减值损失(新) | -5,497,838.89 | -103,626,312.79 | -10,588,103.27 | -17,054,582.93 |
| 信用减值损失(新) | -45,828,090.79 | -17,171,300.92 | -25,470,766.68 | -32,726,238.69 |
| 其他收益 | 29,055,479.16 | 210,586,461.02 | 173,426,761.91 | 171,090,090.83 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -55,796,443.46 | 93,837,662.73 | 264,472,673.64 | 272,577,542.61 |
| 加:营业外收入 | 135,532.11 | 2,629,833.14 | 275,756.32 | 137,218.58 |
| 减:营业外支出 | 2,239,304.55 | 28,986,662.99 | 18,596,119.33 | 14,566,377.47 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -57,900,215.9 | 67,480,832.88 | 246,152,310.63 | 258,148,383.72 |
| 减:所得税费用 | -3,758,229.48 | -41,613,689.49 | -24,333,825.64 | -5,448,226.86 |
| 六、净利润 | -54,141,986.42 | 109,094,522.37 | 270,486,136.27 | 263,596,610.58 |
| 持续经营净利润 | -54,141,986.42 | 109,094,522.37 | 270,486,136.27 | 263,596,610.58 |
| 归属于母公司股东的净利润 | -52,776,946.91 | 106,235,425.64 | 266,649,096.74 | 260,480,462.16 |
| 少数股东损益 | -1,365,039.51 | 2,859,096.73 | 3,837,039.53 | 3,116,148.42 |
| (一)基本每股收益 | -0.04 | 0.08 | 0.21 | 0.21 |
| (二)稀释每股收益 | -0.04 | 0.08 | 0.21 | 0.21 |
| 九、综合收益总额 | -54,141,986.42 | 109,094,522.37 | 270,486,136.27 | 263,596,610.58 |
| 归属于母公司股东的综合收益总额 | -52,776,946.91 | 106,235,425.64 | 266,649,096.74 | 260,480,462.16 |
| 归属于少数股东的综合收益总额 | -1,365,039.51 | 2,859,096.73 | 3,837,039.53 | 3,116,148.42 |
| 公告日期 | 2025-04-25 | 2025-04-12 | 2024-10-25 | 2024-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |